Resumen
Exposure to stressful life events and individual differences in the personality trait neuroticism are important risk factors that interact to predict major depressive disorder (MDD). Less is known about their effect on treatment response in depression. Here, we examine whether stressful life events experienced prior to and during treatment interact with neuroticism to predict response to 16-week pharmacotherapy for MDD. Participants included 159 outpatients with MDD who were initially treated with 8 weeks of escitalopram. Those who responded to the initial treatment continued on escitalopram monotherapy, whereas non-responders received 8 weeks of adjunctive aripiprazole. Personality was assessed using the NEO-Five Factor Inventory, and stressful life events were assessed using the Life Events and Difficulties Schedule, a rigorous contextual interview that includes independent ratings of threatening life events. High baseline neuroticism was associated with a lower likelihood of response when patients experienced one or more negative life events before treatment. Secondary analyses indicated that this effect was specific to neuroticism, and not better accounted for by its self-criticism or negative affect facets. Our results suggest that assessing personality and stressful life events at baseline can help clinicians assess which patients will respond to antidepressant therapy and which may need treatment augmentation.
| Idioma original | English |
|---|---|
| Páginas (desde-hasta) | 273-282 |
| Número de páginas | 10 |
| Publicación | Personality and Mental Health |
| Volumen | 15 |
| N.º | 4 |
| DOI | |
| Estado | Published - nov. 2021 |
Nota bibliográfica
Funding Information:CAN-BIND is an Integrated Discovery Program carried out in partnership with, and with financial support from, the Ontario Brain Institute, an independent non-profit corporation, funded partially by the Ontario government. The opinions, results, and conclusions are those of the authors and no endorsement by the Ontario Brain Institute is intended or should be inferred. Additional funding is provided by the Canadian Institutes of Health Research (CIHR), Lundbeck, Bristol-Myers Squibb, Pfizer, and Servier. Funding and/or in kind support is also provided by the investigators' universities and academic institutions. Additional grant funding was provided by the National Institute of Mental Health (Grant No. K01-MH123915 to TAA). All study medications are independently purchased at wholesale market values.
Funding Information:
CAN‐BIND is an Integrated Discovery Program carried out in partnership with, and with financial support from, the Ontario Brain Institute, an independent non‐profit corporation, funded partially by the Ontario government. The opinions, results, and conclusions are those of the authors and no endorsement by the Ontario Brain Institute is intended or should be inferred. Additional funding is provided by the Canadian Institutes of Health Research (CIHR), Lundbeck, Bristol‐Myers Squibb, Pfizer, and Servier. Funding and/or in kind support is also provided by the investigators' universities and academic institutions. Additional grant funding was provided by the National Institute of Mental Health (Grant No. K01‐MH123915 to TAA). All study medications are independently purchased at wholesale market values. 1
Publisher Copyright:
© 2021 John Wiley & Sons, Ltd.
ASJC Scopus Subject Areas
- Phychiatric Mental Health
- Health Policy
- Psychiatry and Mental health
PubMed: MeSH publication types
- Journal Article
- Research Support, N.I.H., Extramural
- Research Support, Non-U.S. Gov't
ODS de las Naciones Unidas
Este resultado contribuye a los siguientes Objetivos de Desarrollo Sostenible
